Although SGLT2 inhibitors are generally well tolerated and offer considerable benefits in patients with T2DM, heart failure, and chronic kidney disease, their increasing use has led to a shift in prescribing patterns. This evidence concerns the gene SLC5A2 and chronic kidney disease.